Biovail Files Citalopram NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovail's NDA for an orally disintegrating tablet form of the antidepressant citalopram (Forest's Celexa) has a user fee date in February.
You may also be interested in...
FDA Approves Biovail's Citalopram
The antidepressant is not an AB-rated generic.
FDA Approves Biovail's Citalopram
The antidepressant is not an AB-rated generic.
Forest Expects Multiple Celexa Generics To Enter Market In January
Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.